Difference between revisions of "Team:SDU-Denmark"

Revision as of 02:57, 19 September 2015

Welcome

Interactive wiki-tour

Menu

You really should try our interactive wiki tour instead!

But if you are looking for a specific page - you are in the right place.

Introduction

Antibody issue

PAST

Process

Results

Practices

What is Next

PAST

Peptide Aptamer Screening using Two-Hybrid System

This is a project focusing on finding an alternative to the traditional antibody production. Currently, all marketed antibodies are made in vitro, by exploiting mammalian cell's immune system and its ability to produce antibodies against a certain antigen. Increasing demands implies the necessity of quicker methods to drive down the costs of production, both because of economical issues and the expense of animal lives. These are exactly the issues that we have been trying to accommodate. Sounds interesting, right? Take a tour through our wiki either by the menu function or the tourmenu. Enjoy!

Medal Requirements

Want to check out which requirements we have fulfilled?

Click here to get directed to the requirements page.

Our team

We are the SDU-Denmark 2015 team!

Click here to be directed to our team page.

@@ Line 46: / Line 46: @@
 <div class="boxgrid contentBorder boxgridSmall" id="box2" >
-<img src="https://static.igem.org/mediawiki/2015/7/7e/SDU2015_FrontpageMedals.jpg">
+<img src="https://static.igem.org/mediawiki/2015/1/13/SDU2015_Frontpageimage2_500x.png">
 <a class="cover boxcaption" style="top: 465px" href="https://2015.igem.org/Team:SDU-Denmark/Tour14">
 <h2 class="onBlack">Medal Requirements</h2>
-<p class="onBlackIntro">
+<p class="onBlackIntro" style="text-align:left;">
-Wnat to check out which requirements we have fulfilled?
+Want to check out which requirements we have fulfilled?
 </p>
 <p class="onBlack" style="text-align:left;">
@@ Line 68: / Line 68: @@
 We are the SDU-Denmark 2015 team!
 </p>
+<p class="onBlack" style="text-align:left;">
 Click here to be directed to our team page.
+</p>
 </a>
 </div>